# A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

> **NCT04020055** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amicus Therapeutics** · enrollment: 14 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** migalastat HCl 150 mg

## Key facts

- **NCT ID:** NCT04020055
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-31
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020055, "A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04020055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*